公开(公告)号：US11999802B2

公开(公告)日：2024-06-04

申请号：US16757026

申请日：2018-10-18

Applicant: Novartis AG

Inventor： James E. Bradner ,  Andrei Golosov ,  Carleton Proctor Goold ,  Carla Patricia Pinto Guimaraes ,  Marc Horst Peter Hild ,  Gregory Motz ,  Nathan Thomas Ross ,  Jonathan M. Solomon ,  Rohan Eric John Beckwith ,  Seth Carbonneau

IPC: C07K19/00 ,  A61K31/4545 ,  A61K31/46 ,  A61K35/12 ,  C07D209/48 ,  C07D213/81 ,  C07D401/14 ,  C07D451/02 ,  C07K14/435 ,  C07K14/705 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C12N9/06 ,  C12N15/63 ,  C12N15/86 ,  G01N33/68

CPC classification number: C07K19/00 ,  A61K31/4545 ,  A61K31/46 ,  A61K35/12 ,  C07D209/48 ,  C07D213/81 ,  C07D401/14 ,  C07D451/02 ,  C07K14/435 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70575 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2815 ,  C07K16/2863 ,  C07K16/2875 ,  C07K16/2887 ,  C07K16/2896 ,  C12N9/003 ,  C12N15/63 ,  C12N15/86 ,  C12Y105/01003 ,  G01N33/6803 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/20 ,  C07K2319/35 ,  C07K2319/81 ,  C07K2319/95 ,  C12N2740/15043

Abstract: The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a COF1/CRBN-binding polypeptide, COF2/CRBN-binding polypeptide, or COF3/CRBN-binding polypeptide and a heterologous polypeptide of interest.

公开(公告)号：US20200339704A1

公开(公告)日：2020-10-29

申请号：US16757026

申请日：2018-10-18

Applicant: James E. BRADNER ,  Novartis AG

Inventor： James E. Bradner ,  Andrei Golosov ,  Carleton Proctor Goold ,  Carla Patricia Pinto Guimaraes ,  Marc Horst Peter Hild ,  Gregory Motz ,  Nathan Thomas Ross ,  Jonathan M. Solomon ,  Rohan Eric John Beckwith ,  Seth Carbonneau

IPC: C07K19/00 ,  C07K16/18 ,  C12N9/06 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  G01N33/68 ,  C12N15/86 ,  A61K35/12 ,  A61K31/4545 ,  C07D401/14 ,  C07D451/02 ,  A61K31/46

Abstract: The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a COF1/CRBN-binding polypeptide, COF2/CRBN-binding polypeptide, or COF3/CRBN-binding polypeptide and a heterologous polypeptide of interest.

公开(公告)号：US20230139800A1

公开(公告)日：2023-05-04

申请号：US17933687

申请日：2022-09-20

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Motz ,  Frederic Dixon Bushman ,  Joseph A. Fraietta ,  Carl H. June ,  Jan J. Melenhorst ,  Christopher Loren Nobles ,  Regina M. Young

IPC: C07K14/47 ,  C07K14/705 ,  C12N9/02 ,  A61K39/00 ,  A61P35/00 ,  A61K35/17 ,  A61K39/395

Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.

公开(公告)号：US20180258149A1

公开(公告)日：2018-09-13

申请号：US15760519

申请日：2016-09-16

Applicant: Gregory MOTZ ,  Frederic Dixon BUSHMAN ,  Joseph A. FRAIETTA ,  Carl H. JUNE ,  Jan J. MELENHORST ,  Christopher Loren NOBLES ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Motz ,  Frederic Dixon Bushman ,  Joseph A. Fraietta ,  Carl H. June ,  Jan J. Melenhorst ,  Christopher Loren Nobles ,  Regina M. Young

IPC: C07K14/47 ,  C12N9/02 ,  C07K14/705 ,  A61K35/17 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  C07K14/70503 ,  C12N9/0069 ,  C12Y113/11

Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.

公开(公告)号：US20240384007A1

公开(公告)日：2024-11-21

申请号：US18629314

申请日：2024-04-08

Applicant: Novartis AG

Inventor： James E. Bradner ,  Andrei Golosov ,  Carleton Proctor Goold ,  Carla Patricia Pinto Guimaraes ,  Marc Horst Peter Hild ,  Gregory Motz ,  Nathan Thomas Ross ,  Jonathan M. Solomon ,  Rohan Eric John Beckwith ,  Seth Carbonneau

IPC: C07K19/00 ,  A61K31/4545 ,  A61K31/46 ,  A61K35/12 ,  C07D209/48 ,  C07D213/81 ,  C07D401/14 ,  C07D451/02 ,  C07K14/435 ,  C07K14/705 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C12N9/06 ,  C12N15/63 ,  C12N15/86 ,  G01N33/68

Abstract: The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a COF1/CRBN-binding polypeptide, COF2/CRBN-binding polypeptide, or COF3/CRBN-binding polypeptide and a heterologous polypeptide of interest.

公开(公告)号：US20230071283A1

公开(公告)日：2023-03-09

申请号：US16093758

申请日：2017-04-14

Applicant: Andrei Golosov ,  Carla Patricia Pinto Guimaraes ,  Gregory Motz ,  Michael C. Milone ,  Christoph T. Ellebrecht ,  Aimee S. Payne ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Andrei Golosov ,  Carla Patricia Pinto Guimaraes ,  Gregory Motz ,  Michael C. Milone ,  Christoph T. Ellebrecht ,  Aimee S. Payne

IPC: C07K14/725

Abstract: Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two. Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer. Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.

公开(公告)号：US20190298715A1

公开(公告)日：2019-10-03

申请号：US16338085

申请日：2017-09-29

Applicant: Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao

IPC: A61K31/496 ,  A61K31/444 ,  C12N15/113 ,  A61K31/404 ,  A61K35/17

Abstract: Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

公开(公告)号：US20190000880A1

公开(公告)日：2019-01-03

申请号：US16066855

申请日：2016-12-30

Applicant: Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Gregory Motz ,  Konstantinos John Mavrakias ,  Jinbiao Liu ,  Lei Liu ,  Qiangang Zheng ,  Guoliang Xun ,  Qitao Xiao

IPC: A61K35/17 ,  C07D207/34 ,  C12N5/0783 ,  C07D401/14 ,  C12N15/113 ,  A61P35/00 ,  C07K16/28 ,  C07K16/24 ,  C07K16/30

Abstract: Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.